Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis
Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis
复制标题
DOI：
10.1016/j.schres.2017.03.015
复制
发表时间：
2017-12-01
影响因子：
4.5
通讯作者：
Kasai, Kiyoto
中科院分区：
文献类型：
--
作者：
Koshiyama, Daisuke;Kirihara, Kenji;Kasai, Kiyoto
听觉失匹配负波（MMN）是事件相关电位的一个组成部分，正逐渐被认为是精神病早期阶段的候选生物标志物。虽然以前的横断面研究表明，小MMN振幅在精神病的早期阶段，它仍然是未知的小MMN振幅是否是由于在早期过程中进行性减少。在这项研究中，我们调查了精神病早期MMN的纵向变化。参与者包括14名首发精神病（FEP）患者，16名超高风险（UHR）患者和16名健康对照组（HC）。我们分别测量了持续时间偏差（dMMN）和频率偏差（fMMN）的MMN。与HC相比，FEP和UHR中的dMMN振幅显著较小，HC中的dMMN振幅未显示出随时间的进行性降低。fMMN的振幅在各组之间没有差异，也没有显示进展。随访时间的长短与FEP或UHR中任一异常型MMN的纵向变化之间无显著相关性。这些结果表明，dMMN是精神病早期阶段的一个特征标记，精神病早期阶段的小dMMN振幅可能反映了发育过程的改变，而不是进行性脑病理。在精神病的早期阶段，fMMN的振幅可能不会改变。这些发现可能有助于未来建立MMN作为精神病早期阶段的生物标志物。(C)2017爱思唯尔B.V.保留所有权利。
The auditory mismatch negativity (MMN) is a component of event-related potentials, which is being increasingly recognized as a candidate biomarker for early stages of psychosis. Although previous cross-sectional studies have demonstrated small MMN amplitude in early stages of psychosis, it remains unknown whether small MMN amplitude is due to progressive reduction during the early course. In this study, we investigated longitudinal changes of MMN in early stages of psychosis. Participant included 14 patients with first-episode psychosis (FEP), 16 individuals with ultra-high risk (UHR), and 16 healthy control subjects (HC). We measured MMN in response to duration deviants (dMMN) and that in response to frequency deviants (fMMN), respectively. The amplitudes of dMMN in FEP and UHRwere significantly smaller in comparison to those in HC, which did not show a progressive decrease over time. The amplitude of fMMN did not differ among groups, which again did not show progression. There was no significant correlation between the length of the follow-up period and the longitudinal change of either deviant-type MMN in the FEP or UHR. These results suggest that dMMN is a trait marker in the early stages of psychosis, and that small dMMN amplitude in early stages of psychosis may reflect altered developmental process rather than progressive brain pathology. The amplitude of fMMN may not alter in early stages of psychosis. These findings may contribute to the future establishment of MMN as a biomarker in early stages of psychosis. (C) 2017 Elsevier B.V. All rights reserved.